Loading
A phase 1 trial of BHV-1530 run by Biohaven Therapeutics Ltd., now recruiting.
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT06874335 by Biohaven Therapeutics Ltd., with 140 participants planned, started 2025-03-20, primary completion expected 2029-03. Conditions recorded: Solid Tumor. Interventions recorded: BHV-1530, Cemiplimab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/